Cost-effectiveness of nanomedicine: the path to a future successful and dominant market?

被引：0
|
作者：
Bosetti, Rita [1 ]
机构：
[1] Univ Liege, Biomech Res Unit, BE-4000 Liege, Belgium
来源：
NANOMEDICINE | 2015年 / 10卷 / 12期
关键词：
challenges; commercialization; cost-effectiveness analysis; nanotherapeutics; DECISION-MAKING; NANOPARTICLES; OBSTACLES;
D O I：
10.2217/NNM.15.74
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Market uptake of 'expensive' nanotherapeutics could, however, increase significantly by the use of comprehensive standardized cost-effectiveness analyses.
引用
收藏
页码：1851 / 1853
页数：3
相关论文
共 50 条
  • [21] The Cost-Effectiveness of Atypicals in the UK
    Heeg, Bart
    Buskens, Erik
    Botteman, Marc
    Caleo, Sue
    Ingham, Mike
    Damen, Joep
    de Charro, Frank
    van Hout, Ben
    VALUE IN HEALTH, 2008, 11 (07) : 1007 - 1021
  • [22] Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual
    Doble, Brett
    Harris, Anthony
    Thomas, David M.
    Fox, Stephen
    Lorgelly, Paula
    PHARMACOGENOMICS, 2013, 14 (12) : 1405 - 1417
  • [23] Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve
    Sendi, Pedram
    PHARMACOECONOMICS, 2021, 39 (02) : 161 - 169
  • [24] On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
    Vallejo-Torres, Laura
    Garcia-Lorenzo, Borja
    Castilla, Ivan
    Valcarcel-Nazco, Cristina
    Garcia-Perez, Lidia
    Linertova, Renata
    Polentinos-Castro, Elena
    Serrano-Aguilar, Pedro
    VALUE IN HEALTH, 2016, 19 (05) : 558 - 566
  • [25] Sustainability of Behavioral Interventions: Beyond Cost-Effectiveness Analysis
    Brown, Paul M.
    Cameron, Linda D.
    Ramondt, Steven
    INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2015, 22 (03) : 425 - 433
  • [26] Does Medicare Have an Implicit Cost-Effectiveness Threshold?
    Chambers, James D.
    Neumann, Peter J.
    Buxton, Martin J.
    MEDICAL DECISION MAKING, 2010, 30 (04) : E14 - E27
  • [27] A Framework of Cost-Effectiveness Analysis for Alternative Energy Strategies
    Qin, Ruwen
    Grasman, Scott E.
    Long, Suzanna
    Lin, Yaqin
    Thomas, Mathew
    ENGINEERING MANAGEMENT JOURNAL, 2012, 24 (04) : 18 - 35
  • [28] A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities
    Zimovetz, Evelina A.
    Wilson, Koo
    Samuel, Miny
    Beard, Stephen M.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2011, 17 (02) : 288 - 297
  • [29] A cceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
    Griffiths, Elizabeth A.
    Hendrich, Janek K.
    Stoddart, Samuel D. R.
    Walsh, Sean C. M.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 463 - 476
  • [30] The History and Future of the "ISPOR Value Flower": Addressing Limitations of Conventional Cost-Effectiveness Analysis
    Neumann, Peter J.
    Garrison, Louis P.
    Willke, Richard J.
    VALUE IN HEALTH, 2022, 25 (04) : 558 - 565
12345